Thematic areas of research:
Image
To top
Unit
Cancer, Heterogeneity, Instability and Plasticity - CHIP (U830)
The INSERM/Institut Curie U830 conducts both basic and applied research in the field of cancer biology. Located on the Paris site of Institut Curie, it strongly benefits from the outstanding scientific environment of the Institut Curie research center and from the proximity of the cancer hospital.
Teams
Key figures
76
publications in 2020
9
ongoing European projects in 2020
2
ongoing ERC in 2020
Key publications
All publications
-
Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal MelanomasJNCI: Journal of the National Cancer Institute
-
-
-
-
-
News
All news
-
Triple-negative breast cancer : First patients included in a clinical trial at Institut CurieTriple-negative breast cancers represent about 15% of cases, affect younger women more and remain difficult to treat. The new "Skyline" clinical trial, which has just opened as part of the RHU CASSIOPEIA Future Investment Program at Institut Curie, the 1st European center for breast cancer management, has a double objective: to evaluate the effectiveness of a new combination of two immunotherapies in combination with chemotherapy in women with triple-negative breast cancer and to better visualize the cancer and its possible metastases thanks to innovative imaging used for the first time in France.15/04/2024 -
Promising results from Institut Curie presented at the AACR congressFrom April 5 to 10 2024 in San Diego (United States), the scientific community and medical community will be meeting for the annual congress of the American Association for Cancer Research. This is an opportunity for Institut Curie researchers and doctors to present their advances in the various fields of cancer research.05/04/2024 -
Institut Curie joins global Cancer Grand Challenges team taking on Solid tumors in childrenThe doctor Olivier Delattre, Diversity and plasticity of childhood tumors team leader and director of the research unit Cancer, heterogeneity, instability, and plasticity at Institut Curie, is part of a global, interdisciplinary team of researchers, labeled team KOODAC, that have been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle solid tumors in children.06/03/2024 -
World Triple Negative Breast Cancer Day: innovation to cure more womenWorld Triple Negative Breast Cancer Day, held on March 3rd, is a reminder that triple-negative breast cancers remain the most difficult to treat, and that only innovation and dynamic research can bring hope of curing more patients.01/03/2024 -
New therapeutic avenues to improve the treatment of ovarian cancerBy studying for the first time the effects of chemotherapy on certain cells of the tumor microenvironment, a team from Institut Curie and Inserm led by Dr. Fatima Mechta-Grigoriou is taking a step forward in understanding the mechanisms of resistance to chemotherapy in patients with ovarian cancer. Indeed, scientists have managed to identify a population of fibroblasts (support cells) capable of inhibiting the antitumor action of certain immune cells even after treatment. Published in Nature Communications, these results open the way to potential anti-cancer therapeutic applications.22/02/2024 -
Un nouveau projet d’envergure pour comprendre et combattre le mélanome uvéalL’Institut Curie a lancé en septembre dernier un projet ambitieux dans la lutte contre le mélanome uvéal, le cancer de l’œil le plus fréquent chez l’adulte. En collaboration avec le Melanoma Patients Network Europe (MPNE) et soutenu par le Secrétaire adjoint américain à la défense pour les affaires sanitaires et approuvé par le ministère américain de la Défense, le projet a pour objectifs d’identifier la prédisposition génétique, la tumorigenèse ainsi que les réponses immunitaires spécifiques à ce cancer.31/10/2023
Scientific events
All scientific events
2 Jun
2023
Seminar
14h-15h
Mechanisms of Transcriptional Regulation in Drosophila & Mammalian Cells
Abstract
Transcription in higher eukaryotes is highly orchestrated at our ~20K mRNA encoding genes. The levels and cellular patterns of transcription of these genes respond to a spectrum of signals including those occurring in response to our normal program of development, in response to changes in nutrition and environment, and importantly, in response to infection and other disease states. Th
Transcription in higher eukaryotes is highly orchestrated at our ~20K mRNA encoding genes. The levels and cellular patterns of transcription of these genes respond to a spectrum of signals including those occurring in response to our normal program of development, in response to changes in nutrition and environment, and importantly, in response to infection and other disease states. Th
16 Jun
2022
Seminar
12h-13h
Using genomics to invesIgate radiaIon-related thyroid cancer following the Chernobyl accident in 1986
Following the Chernobyl nuclear power plant accident in Ukraine in 1986, increased childhood exposure to radioactive iodine (131I), which occurred primarily through consumption of contaminated food sources, has been consistently associated with increased risk of developing papillary thyroid carcinoma (PTC). In a landscape analysis of fresh-frozen tumor tissues from the Chernobyl Tissue B